“ bit.bio develops capabilities to produce every human cell type at scale. We believe this will transform the biotech and medicine research landscape and enable a new generation of cell therapies. Synthetic biology for us is essentially the transition of biology as we know it to engineering and that’s the approach we are taking to cells."
"bit.bio cells address this demand. These cells are physiologically relevant and phenotypically characterised, and for the first time, available at scale, offering predictive in vitro cells for drug screening.”